CYCC - Cyclacel Pharmaceuticals Growth-Adjusted Payback Ratio

Cyclacel Pharmaceuticals (CYCC) is optimizing costs through flexible global supply chains for active substances. The financial model relies on grants and partnerships to develop leukemia treatments. The current PEG ratio clearly confirms the market valuation, where the actual value is 0.00. However, a liquidity deficit and uncertainty regarding fadraciclib test outcomes create significant risks for investors.

CYCC Cyclacel, Inc. Price/Earnings to Growth Ratio (07/04/2022 - 09/12/2025)

Metric breakdowns and analytics for Cyclacel Pharmaceuticals (CYCC)

- current price and projected stock value:

Price Chart Cyclacel Pharmaceuticals, Inc.|CYCC - Consensus Target

- market capitalization statistics:

Market Value Cyclacel Pharmaceuticals Inc.|CYCC - Total Company Value

- book capitalization indicators:

Net Asset Value per Share Cyclacel|CYCC - Company Book Value|Capitalization to Book Value Ratio cyclacel.com|CYCC - Company Total Assets

- issuer credit burden and liquidity indicators:

- earnings and multiples data:

CYCC - Net Income|Expected Net Profit Cyclacel Pharmaceuticals|CYCC - Price to Earnings Ratio|Future Price to Earnings Multiple Cyclacel, Inc.|CYCC - Price/Earnings to Growth Multiple|Enterprise Value to Operating Income Before Depreciation Ratio Cyclacel Pharmaceuticals Inc.|CYCC - Operating profit EBITDA|Earnings per share for the trailing year Cyclacel|CYCC - Net earnings per share (EPS TTM)|Earnings per share growth in annualized terms for the last twelve months cyclacel.com|CYCC - Earnings per share growth in current year|Expected earnings per share trend next year Cyclacel Pharmaceuticals

Fundamental company analysis:Cyclacel Pharmaceuticals, Inc. CYCC

Original product of Cyclacel Pharmaceuticals Inc.

The PEG ratio compares the current market multiple with net income growth, allowing for the determination of an asset's undervaluation relative to its expansion. While analyzing the current PEG level helps identify growth potential, for Cyclacel Pharmaceuticals (CYCC), this metric remains speculative, as the company is in the early stages of clinical trials and finances its operations through securities issuance.

Competitors of Cyclacel Pharmaceuticals